AHA Coding Clinic® for ICD-9 - 2013 Quarter 4; Ask the Editor
Methylenetetrahydrofolate Reductase Heterozygosity/Deficiency and PAI-1 Polymorphism
The patient has been diagnosed with methylenetetrahydrofolate reductase (MTHFR) heterozygosity and PAI-1 polymorphism. The provider documented, “aspirin prescribed for MTHFR mutation.” After researching the subject, it is unclear if heterozygosity is the same as MTHFR deficiency. Is code 270.4 assigned for the MTHFR heterozygosity? Additionally, what is the code assignment for PAI-1 polymorphism? ...
Subscribe or sign in to view the full article.
Article Overview
This article discusses how to approach a documentation question involving MTHFR heterozygosity or deficiency and PAI-1 polymorphism. It is intended for coding professionals who need to distinguish among related genetic findings and understand the article’s general guidance on code assignment and documentation review.
Why This Topic Matters
Genetic and laboratory-related documentation can be ambiguous, and correct code selection depends on precise provider wording. This article helps readers determine whether the documented condition is being reported as a susceptibility, a deficiency, or another genetic finding.
What You Will Learn
- How the article frames a documentation question involving MTHFR and PAI-1 findings.
- Why provider clarification may be needed when genetic terminology is ambiguous.
- The general coding topic area associated with genetic susceptibility and polymorphism documentation.
- How the article addresses the relationship between a gene finding and a deficiency diagnosis.
Who Should Read This
- Medical coders
- Coding auditors
- Clinical documentation specialists
- Revenue cycle staff
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com